| 000 | 01845 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250514225742.0 | ||
| 264 | 0 | _c20060223 | |
| 008 | 200602s 0 0 eng d | ||
| 022 | _a1530-6860 | ||
| 024 | 7 |
_a10.1096/fj.04-3010fje _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _avan der Stelt, Mario | |
| 245 | 0 | 0 |
_aA role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. _h[electronic resource] |
| 260 |
_bFASEB journal : official publication of the Federation of American Societies for Experimental Biology _cJul 2005 |
||
| 300 |
_a1140-2 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aArachidonic Acids _xanalysis |
| 650 | 0 | 4 | _aCallithrix |
| 650 | 0 | 4 |
_aCannabinoid Receptor Modulators _xanalysis |
| 650 | 0 | 4 |
_aDyskinesia, Drug-Induced _xetiology |
| 650 | 0 | 4 | _aEndocannabinoids |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGlycerides _xanalysis |
| 650 | 0 | 4 |
_aLevodopa _xtoxicity |
| 650 | 0 | 4 |
_aMPTP Poisoning _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPiperidines _xtherapeutic use |
| 650 | 0 | 4 | _aPolyunsaturated Alkamides |
| 650 | 0 | 4 |
_aPyrazoles _xtherapeutic use |
| 650 | 0 | 4 |
_aReceptor, Cannabinoid, CB1 _xagonists |
| 650 | 0 | 4 | _aRimonabant |
| 650 | 0 | 4 |
_agamma-Aminobutyric Acid _xmetabolism |
| 700 | 1 | _aFox, Susan H | |
| 700 | 1 | _aHill, Michael | |
| 700 | 1 | _aCrossman, Alan R | |
| 700 | 1 | _aPetrosino, Stefania | |
| 700 | 1 | _aDi Marzo, Vincenzo | |
| 700 | 1 | _aBrotchie, Jonathan M | |
| 773 | 0 |
_tFASEB journal : official publication of the Federation of American Societies for Experimental Biology _gvol. 19 _gno. 9 _gp. 1140-2 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1096/fj.04-3010fje _zAvailable from publisher's website |
| 999 |
_c15557100 _d15557100 |
||